Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Inclusion Criteria:

• Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive

Exclusion Criteria:

• Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative